Neuromuscular

The director of the Massachusetts General Hospital ALS Care Center spoke on the importance of data-based registries and how they can grow ALS research.

Here's what is coming soon to NeurologyLive.

The director of the Massachusetts General Hospital ALS Care Center discussed the origins of ‘The Data is Here’ campaign and the reason to launch it now.

Neurology News Network for the week ending January 30, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 29, 2021.

The primary investigator of the phase 4 RESPOND study discussed the role that postmarketing studies can play in assessing treatments for SMA.

Brian Frederick, PhD, discusses how the short life expectancy after diagnosis leads many patients with ALS to lose their lives before receiving disability benefits.

Researchers hope that R-loop modulation may hold potential in the future treatment of ALS.

The director of the Massachusetts General Hospital ALS Care Center sat down to discuss ‘The Data is Here’ campaign from Answer ALS, the world’s largest open-sourced ALS data portal.

The primary investigator of RESPOND discussed the trial’s goals and measures, as well as insight into why clinical trials like it are important in spinal muscular atrophy.

Preclinical studies have shown that the homeoprotein hEN1 is essential for the survival and maintenance of spinal cord alpha motor neurons that innervates muscles throughout the body.

Brian Wainger, MD, PhD, assistant professor of neurology and anesthesiology, Harvard Medical School, discussed the recently published phase 2 trial a repurposed epilepsy drug in patients with ALS.

Here's what is coming soon to NeurologyLive.

The assistant professor of neurology and anesthesiology at Harvard Medical School discussed non-traditional ways ALS research is changing and where the focus should continue to be.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 22, 2021.

Michael Benatar, MD, PhD, executive director, ALS Center at the University of Miami, discusses collaborating with Biogen on a clinical study evalutating tofersen.

The team Cure SMA endurance program goes virtual - sign up now.

The average number of inpatient claims per year was higher for patients with SMA than their matched non-SMA patients, with respiratory illness the most common reason for an inpatient admission among all patients with SMA.

NM was found to have a stable disease course and the most common classification was typical congenital.

The webinars, for adults and children with SMA, were produced in conjunction with Biogen and the Luke 18:1 Foundation.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending January 16, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 15, 2021.

The assistant professor of neurology and anesthesiology at Harvard Medical School discussed the landscape of ALS treatments and his outlook on how the future might evolve.

The Pfizer candidate PF-06939926 has also received fast track, orphan drug, and rare pediatric disease designations from the FDA.